The mechanism of the renal excretion of carumonam (CRMN) was investigated in rats, rabbits, dogs, and monkeys. Stop-flow analysis in dogs demonstrated that CRMN is exclusively excreted by glomerular filtration. There was no specific CRMN peak corresponding to the peak of p-aminohippuric acid (PAH) secretion or to the trough of Na+-K+ reabsorption in the stop-flow pattern. Although the PAH peak disappeared when probenecid was administered, the CRMN stop-flow pattern showed no change. In rabbits, however, the CRMN concentration peak corresponding with the PAH peak was detected in the stop-flow pattern; the CRMN peak disappeared when probenecid was administered. The pharmacokinetic parameters in plasma, such as the area under the concentration-time curve, the half-life, and the clearance rate, were affected by probenecid in rats, rabbits, and monkeys, but not in dogs. The results suggest that the renal excretion of CRMN in dogs takes place exclusively through glomerular filtration. In rats, rabbits, and monkeys, however, CRMN is excreted through both glomerular filtration and renal tubular secretion.
tivities against gram-negative bacteria (2) . In experimental animals (3) and humans (11) , CRMN is eliminated predominantly by renal excretion after parenteral administration and is metabolized only to a small extent (3) .
In the present study, the mechanism of renal CRMN excretion in dogs and rabbits was examined by renal clearance and stop-flow analysis. The effects of probenecid administration on the plasma pharmacokinetics in rats and monkeys as well as in rabbits and dogs were also examined.
MATERIALS AND METHODS Antibiotic and chemicals. CRMN was prepared in our research division. Other chemicals were obtained commercially: ini4lin, mannitol, and creatinine (CR) from Wako Pure Chemical Industries, Ltd.; sodium p-aminohippurate (PAH) and probenecid from Sigma Chemical Co. Ltd.; and sodium pentobarbital (Nembutal) from Abbott Laboratories.
Animals. Five-week-old male Slc:ICR mice weighing 20 to 25 g, 7-week-old male Jcl:SD rats weighing 210 to 250 g, 4-month-old male New Zealand White rabbits weighing 2.5 to 3.5 kg, 10-month-old male and female beagle dogs weighing 10 to 12 kg, and male and female cynomolgus monkeys weighing 2.8 to 3.7 kg were used. They were deprived of feed for 16 to 18 h before the antibiotic was administered; water was given ad libitum.
Operative procedures. Animals (dogs and rabbits) were anesthetized with 30 mg of sodium pentobarbital per kg administered intravenously. After the trachea was cannulated, the abdomen was opened with a midline incision and both ureters were cannulated with polyethylene tubing through which urine was collected. The left kidney only was used for occlusion. The left femoral vein and the right femoral artery were catheterized with polyethylene tubing through which the drug solutions were administered and the blood was sampled, respectively. (ii) Rabbits. Four male rabbits were used. The experimental design and procedure were the same as those just described for dogs, except that the concentration of mannitol was 10%. Urine Analysis of plasma and urine specimens. Blood samples were centrifuged at 2,000 x g for 10 tnin in the cold, and the plasma was separated. The serial urine sample volumes were measured by weighing. Plasma and urine samples were stored at -80°C until assayed.
CRMN in the plasma and urine samples was assayed by the agar well method with Escherichia coli NIHJ as the test organism (3). The sensitivity of this method was about 0.1 pLg/ml. The precision in terms of variation coefficient of replicate analyses (n = 8) was ±7.0%. In addition, high-pressure liquid chromatography (3) was used to confirm the concentrations of CRMN in samples. The detection limit for CRMN was l ,ug/ml with a precision of <2%. There was good agreement between the results obtained by the bioassay and those obtained by high-pressure liquid chromatography. Plasma and urine samples were analyzed for inulin by the method of Schreiner (8) Probenecid had almost no effect on the renal clearance ratio of CRMN; the clearance ratios were approximately 1.0.
To further evaluate the contribution of the renal tubules in CRMN excretion, we conducted a stop-flow analysis. The location of excretion from the proximal renal tubules and of reabsorption through the distal renal tubules was determined by using PAH, and sodium and potassium, respectively, as markers. Inulin was administered as a marker of glomerular urine. The ratio of the CR concentration in urine to that in plasma (U/P CR) was calculated as a parameter of concentrated urine. A typical stop-flow pattern is shown in Fig. 1 . The ratio of the urine to plasma concentration (U/P) of each component divided by U/P CR is plotted on the ordinate.
In the stop-flow pattern of CRMN, no specific CRMN peak or trough was found corresponding to the PAH peak or to the sodium and potassium trough area. When probenecid was administered, the stop-flow pattern of CRMN showed no significant change, whereas the PAH peak disappeared.
Rabbits. Table 2 shows the renal clearance of CRMN in rabbits. The clearance ratio of CRMN to CR was approximately 1.7 and was not dependent on the concentration in plasma, which ranged from 21 to 55 pLg/ml. Probenecid induced a marked reduction in the clearance of CRMN.
A typical stop-flow pattern is shown in Fig. 2 . The CRMN peak corresponded with the PAH peak. After probenecid was administered, both the CRMN and PAH peaks disappeared. These results indicate that CRMN is excreted by glomerular filtration (about 60%) and tubular secretion (about 40%) in rabbits ( Fig. 3 ; the pharmacokinetic parameters (AUC, half-life, and CL) are listed in Table 3 . When probenecid was administered, there were no significant changes in the concentration of CRMN in plasma in dogs, whereas that in rats, rabbits, and monkeys increased significantly, as compared with those observed when probenecid was not administered. The , Before probenecid was administered; ----, after probenecid was administered. U/P, Concentration in urine/concentration in plasma.
biological half-life in rats, rabbits, and monkeys was 0.28, 1.61, and 0.96 h with CRMN alone; probenecid extended the half-life to 0.36, 1.97, and 1.31 h, respectively.
DISCUSSION
The results of the present investigations in dogs suggest that the renal excretion of CRMN takes place exclusively through glomerular filtration. The renal clearance of CRMN in dogs was almost equal to the CR clearance (Table 1 ). In the stop-flow pattern of CRMN in dogs (Fig. 1) , no definite peak of CRMN was found corresponding to the peak of PAH. When probenecid was administered the PAH peak disappeared, but the stop-flow pattern of CRMN showed no change. In addition, there were no significant changes in the pharmacokinetic parameters of CRMN in dogs given probenecid (Table 3 ; Fig. 3) .
These results indicate that the renal excretion of CRMN in dogs takes place mostly through glomerular filtration and that there is little or no contribution from renal tubular secretion.
In rabbits, however, both glomerular filtration and renal tubular secretion are involved in the excretion of CRMN. The renal clearance ratio of CRMN to CR was about 1.7, indicating that renal tubular secretion plays a part in the excretion process of CRMN (Table 2 ). In the stop-flow analysis in rabbits, CRMN showed a peak corresponding with the PAH stop-flow pattern, and both the CRMN and PAH peaks disappeared when probenecid was administered. Renal tubular secretion was found to be about 40% of the renal excretion of CRMN. The pharmacokinetic parameters of CRMN in rats, rabbits, and monkeys were significantly changed by probenecid, indicating that renal tubular secretion, in addition to glomerular filtration, contributes to renal excretion of CRMN in these animals (Table 3 ; Fig. 3) .
Recently, Yoshida et al. (12) reported that [14C]CRMN was eliminated by both glomerular filtration (67%) and tubular secretion (33%) in rats. In mice, probenecid caused slight changes in the pharmacokinetic parameters, suggesting that the tubular secretion is also involved, as in rats (unpublished data).
In humans, probenecid administered concomitantly to healthy volunteers does not affect the renal clearance or urinary excretion of CRMN (11) , indicating that the renal elimination of this antibiotic occurs exclusively by glomerular filtration, as in dogs.
Thus, the mechanisms of renal excretion of CRMN differ with animal species. In humans and dogs, CRMN is excreted mainly through glomerular filtration, and in rats, rabbits, and monkeys, it is excreted through both renal tubular secretion and glomerular filtration.
The renal excretion mechanisms of CRMN in dogs and rabbits are similar to those for ceftizoxime (6) and moxalactam (9) . The results of similar studies with aztreonam closely resemble those obtained with CRMN (unpublished data).
